| Previous Close | Open | Close* |
|---|---|---|
| 0.165 | 0.17 | 0.16 |
| Market Cap | Dividend Yield (Annualized) |
|---|---|
| AUD 46.758M | 0.00% |
| Day Range |
|---|
| 0.16L 0.175 H |
| 52 WEEK HIGH LOW |
|---|
| 0.135L 0.495 H |
| Last Trade | 0.16 |
|---|---|
| Change% | -3.0303 |
| 52 W H/L | 0.495/0.135 |
| EBITDA | -18.328M |
| NPAT After Abnormal Items | -18.667M |
| Equity | 24.118M |
| ROE% | -77.40% |
| Total Liabilities | 2.476M |
| Total Revenue | 5.429M |
| Cash and Cash Equivalents | 14.011M |
| Share price | 0.16 |
|---|---|
| Market Cap | 46.758M |
| Price/Gross Cash Flow | -4.46 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 292.238M |
| 52-Week Range | 0.495-0.135 |
| Gross DPS (AUD) | 0 |
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 3.040 |
| Net Tangible Asset (NTA) | 0.08 |
| P/E ratio | 32.895 |
| Sector P/E | -- |
| EPS | -6.41 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -- |
| Gross Cash Flows Per Share | -0.04 |
| Net Gearing | -57.43% |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.08 |
Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.
Suite 3 Level 4, 828 Pacific Highway, GORDON, NSW, AUSTRALIA, 2072
| Ex-Date | Net Dividend | Frank Flag | Period End Date | Type | Payable |
|---|
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Annual) | 2023-09-25 | 2023 |
| Report (Prelim) | 2023-08-24 | 2023 |
| Report (Interim) | 2023-02-20 | 2023 |